YEAR RESEARCHERS PROJECT LINKS
2021 Curtin University “We’re on a Merry-Go-Round”: Reflections of Patients and Carers after Completing Treatment for Sarcoma MDPI
2021 Curtin University Family carers need more support Canberra Times
2020 University of Western Australia, Murdoch University, et al A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies JoVE Journal
2020 University of Western Australia, Murdoch University, Perron Institute, et al Alternative splicing of leptin receptor overlapping transcript in osteosarcoma Society for Experimental Biology and Medicine

News

DATE HEADLINE SUMMARY
June 23, 2021 Precision medicine becomes more accessible for Australians with cancer A new resource developed at the Garvan Institute of Medical Research and The Kinghorn Cancer Centre for oncologists could help make targeted cancer therapies more accessible for Australian patients. The TOPOGRAPH (Therapy-Oriented Precision Oncology Guidelines for Recommending Anti-cancer Pharmaceuticals) database is an online tool that catalogues oncology research to streamline the process of recommending therapeutic treatments in precision cancer medicine. link
June 3, 2021 Gene Behind Childhood Bone Cancer Uncovered Researchers based at the University of North Carolina at Chapel Hill have discovered that the gene OTUD7A controls a cancer-causing protein in Ewing sarcoma, a type of bone cancer mostly impacting children. link
April 21, 2021 Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy Messenger RNA (mRNA) vaccines are a relatively new class of vaccines. They combine the potential of mRNA to encode for almost any protein with an excellent safety profile and a flexible production process. Recently, 2 mRNA vaccines were approved for the first time for human use – to prevent COVID-19 infection – bringing excitement for the future possibilities of this approach for cancer immunotherapy as well as for preventing other infectious diseases. link
March 30, 2021 FDA grants fast track designation to annamycin for sarcoma lung metastases The FDA granted fast track designation to annamycin for the treatment of patients with lung metastases from soft tissue sarcoma, according to a press release from the agent’s manufacturer. link